Task X24: Zika retrospective PCR testing of clinical samples
Task X24: Zika retrospective PCR testing of clinical samples
批准号:
10914349
负责人:
TOM RUDGE
金额:
$2.98万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-28 至 2022-06-30
关键词:
AreaBiologicalBiological ProductsBioterrorismClinicalCommunicable DiseasesContractsDevelopmentEducational workshopEmerging Communicable DiseasesFeasibility StudiesImmunology procedureInvestigational New Drug ApplicationLicensingOffice of Administrative ManagementQualifyingReportingSafetySamplingServicesSite VisitTestingToxicologyTrainingVaccinesValidationZIKAZika virus vaccineefficacy testingevaluation/testingimmunogenicitynovel vaccinesproduct developmenttesting servicesvaccine candidatevaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. Task areas include: 1) administrative management and technical support including training and workshops, and quality oversight and management (site visits, critical stage audits, and final study report audits), 2) development, qualification and validation of immune assays, 3) immunogenicity and efficacy testing, 4) non-clinical and clinical sample testing, and 5) safety/toxicology studies. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金